Efficacy and safety of 3CL protease inhibitors in patients with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials.

The main findings of our analysis were: (1) the number of patients with resolution of symptoms was not significantly different between groups; (2) recovery and symptom alleviation rates showed a favorable trend in patients receiving 3CL protease inhibitors compared to placebo; (3) 3CL protease inhibitors significantly reduced the viral load from baseline as compared with placebo and (4) were associated with higher risk of any adverse events (40.24% vs. 31.26%).

also in 932 other papers

Similarly, a subgroup analysis of patients treated with Ensitrelvir at doses of 125 mg and 250 mg showed a trend toward viral load reduction, though no significant difference was found between the two dosing groups.

also in 28,865 other papers